DekaBank Deutsche Girozentrale’s Iovance Biotherapeutics IOVA Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$1.53M	–	1233
2025 Q4	$1.53M	Hold	100,000	–	–	﹤0.01%	806
2025 Q3	$215K	Hold	100,000	–	–	﹤0.01%	1124
2025 Q2	$170K	Hold	100,000	–	–	﹤0.01%	1157
2025 Q1	$344K	Hold	100,000	–	–	﹤0.01%	1028
2024 Q4	$727K	Hold	100,000	–	–	﹤0.01%	935
2024 Q3	$956K	Hold	100,000	–	–	﹤0.01%	896
2024 Q2	$797K	Hold	100,000	–	–	﹤0.01%	924
2024 Q1	$1.4M	Hold	100,000	–	–	﹤0.01%	815
2023 Q4	$867K	Hold	100,000	–	–	﹤0.01%	926
2023 Q3	$454K	Hold	100,000	–	–	﹤0.01%	1035
2023 Q2	$703K	Hold	100,000	–	–	﹤0.01%	952
2023 Q1	$610K	Hold	100,000	–	–	﹤0.01%	973
2022 Q4	$629K	Hold	100,000	–	–	﹤0.01%	985
2022 Q3	$942K	Sell	100,000 -23,900	-19%	-$276K	﹤0.01%	887
2022 Q2	$1.33M	Hold	123,900	–	–	﹤0.01%	812
2022 Q1	$2.07M	Buy	123,900 +11,300	+10%	+$175K	0.01%	742
2021 Q4	$2.17M	Sell	112,600 -15,000	-12%	-$330K	0.01%	750
2021 Q3	$3.06M	Hold	127,600	–	–	0.01%	639
2021 Q2	$3.34M	Buy	127,600 +64,000	+101%	+$1.66M	0.01%	620
2021 Q1	$1.88M	Hold	63,600	–	–	0.01%	711
2020 Q4	$3.05M	Buy	63,600 +35,800	+129%	+$1.42M	0.01%	562
2020 Q3	$894K	Buy	+27,800	New	+$852K	﹤0.01%	791
2019 Q3	–	Sell	-109,000	Closed	-$2.46M	–	1057
2019 Q2	$2.46M	Buy	109,000 +19,000	+21%	+$286K	0.01%	573
2019 Q1	$1.59M	Buy	90,000 +57,500	+177%	+$559K	0.01%	659
2018 Q4	$288K	Sell	32,500 -57,500	-64%	-$555K	﹤0.01%	916
2018 Q3	$1.59M	Sell	90,000 -2,400	-3%	-$34.1K	0.01%	671
2018 Q2	$1.2M	Buy	92,400 +50,000	+118%	+$731K	0.01%	708
2018 Q1	$700K	Buy	+42,400	New	+$642K	﹤0.01%	800
2016 Q2	–	Sell	-21,000	Closed	-$101K	–	1020
2016 Q1	$101K	Buy	+21,000	New	+$115K	﹤0.01%	955

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

DekaBank Deutsche Girozentrale's IOVA Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 100,000 shares — an estimated $1.53M sold.

DekaBank Deutsche Girozentrale first reported a position in IOVA in Q1 2016 and held it in 29 quarters. The position peaked at $3.34M in Q2 2021. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 100,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.53M.
DekaBank Deutsche Girozentrale first reported a position in Iovance Biotherapeutics in Q1 2016 and held it in 29 quarters.
DekaBank Deutsche Girozentrale's Iovance Biotherapeutics position peaked at $3.34M in Q2 2021.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.